Hims & Hers stock sinks after Q3 results, outlook disappoints
Hims & Hers Health (HIMS) stock dropped 15% after Q3 results. Revenue grew 49% to $890.4M, meeting estimates, but gross margin fell to 57% from 74%. Q4 revenue forecast of $875M-$895M missed expectations of $955.1M. Analysts cited weak outlook and margin concerns.
How this was made
The 30-second read
Why it matters
The earnings miss and weaker guidance trigger a sharp sell‑off, highlighting execution risk in its new strategy.
Market read
The report provides fresh, material data that moves HIMS sharply and may influence peer telehealth stocks.
What to watch
Potential upside from new pharmaceutical partnerships not reflected in the guidance.
Background
Hims & Hers Health is a telehealth provider that recently faced FTC litigation over data sharing and is shifting its product focus.
Ticker impact
Hims & Hers reported Q3 revenue of $890.4M and forecast Q4 revenue below expectations, causing a 15% share drop.
likely further downside as investors price in weaker outlook
Guidance below consensus and margin compression are material negatives for a growth‑focused telehealth firm.
Market effects
Telehealth and digital health stocks may face broader pressure from the guidance miss.
U.S. markets could see a modest pullback in health‑tech indices.
Limited to investors tracking U.S. growth stocks.
Counterpoint
If the company can successfully pivot away from GLP‑1 weight‑loss drugs, the stock may be oversold.
Key entities
- companyHims & Hers Health
U.S. listed telehealth firm (ticker HIMS).
- regulatorFTC
Filed a lawsuit alleging data‑sharing violations.
